Summary
Biogen Idec Inc. (BIIB) announced the appointment of Nancy L. Leaming to its Board of Directors, effective January 8, 2008. Ms. Leaming has been elected as a Class 1 director with a term expiring in 2010 and will fill a previously vacant seat. Her addition to the board is effective immediately, and she will also serve as a member of the Finance and Audit Committee, indicating a focus on financial oversight and governance. This appointment brings new expertise to the board as the company navigates its ongoing business operations.
Key Highlights
- 1Nancy L. Leaming appointed to Biogen Idec's Board of Directors.
- 2Ms. Leaming's term as a Class 1 director expires in 2010.
- 3Her appointment fills a vacant seat on the Board.
- 4Ms. Leaming will serve on the Finance and Audit Committee.
- 5No related-party transactions or special arrangements were disclosed regarding Ms. Leaming's appointment.
- 6Ms. Leaming received an initial grant of 35,000 stock options, an additional grant of 2,200 stock options, and 850 restricted stock units.
- 7All equity awards were granted under the 2006 Non-Employee Directors Equity Plan.
Frequently Asked Questions
Nancy L. Leaming was appointed to the Biogen Idec Board of Directors as a Class 1 director, effective January 8, 2008. She fills a vacant seat and will serve until the 2010 annual meeting. Her appointment is a standard board expansion, and no specific strategic reasons beyond filling a vacancy and leveraging her potential expertise were detailed.
Her appointment to the Finance and Audit Committee suggests that the board values her financial acumen or oversight capabilities. This committee is crucial for reviewing financial reporting, internal controls, and audit processes, indicating a commitment to strong corporate governance.
Upon her appointment, Ms. Leaming received equity compensation under the 2006 Non-Employee Directors Equity Plan. This includes an initial grant of 35,000 stock options, an additional grant of 2,200 stock options, and 850 restricted stock units. This aligns her interests with those of the company's shareholders.
The filing explicitly states that there are no transactions between Ms. Leaming or her immediate family and the Company, nor any arrangements with other parties concerning her appointment. This indicates that the board has vetted her appointment to ensure no apparent conflicts of interest.